{
  "fullName": "S. S. Bajaj",
  "slug": "s-s-bajaj",
  "title": "MD",
  "specialty": "Medicine",
  "geography": {
    "country": "Global",
    "city": "Unknown",
    "region": "Unknown"
  },
  "status": "LIVING",
  "tier": "UNRANKED",
  "rankingScore": 28,
  "hIndex": 136,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Bajaj Auto Limited is an Indian multinational automotive manufacturing company based in Pune. It manufactures motorcycles, scooters and auto rickshaws. Bajaj Auto is a part of the Bajaj Group. It was founded by Jamnalal Bajaj (1889–1942) in Rajasthan in the 1940s.",
  "aiSummary": "S. S. Bajaj is a medicine specialist with an H-index of 136 at Pediatric endocrinology (Member). Has been published in New England Journal of Medicine, The Lancet, JAMA. Based in Unknown, Unknown, Global.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "Pediatric endocrinology"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Pediatric endocrinology",
      "role": "Member",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Medicine"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes",
      "journal": "New England Journal of Medicine",
      "year": 2016,
      "citationCount": 6162,
      "doi": "10.1056/nejmoa1607141",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1607141",
      "verified": true
    },
    {
      "title": "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes",
      "journal": "New England Journal of Medicine",
      "year": 2018,
      "citationCount": 6020,
      "doi": "10.1056/nejmoa1812389",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1812389",
      "verified": true
    },
    {
      "title": "Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus",
      "journal": "New England Journal of Medicine",
      "year": 2013,
      "citationCount": 3417,
      "doi": "10.1056/nejmoa1307684",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1307684",
      "verified": true
    },
    {
      "title": "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial",
      "journal": "The Lancet",
      "year": 2019,
      "citationCount": 2800,
      "doi": "10.1016/s0140-6736(19)31149-3",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(19)31149-3",
      "verified": true
    },
    {
      "title": "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials",
      "journal": "The Lancet",
      "year": 2018,
      "citationCount": 2699,
      "doi": "10.1016/s0140-6736(18)32590-x",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(18)32590-x",
      "verified": true
    },
    {
      "title": "Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome",
      "journal": "New England Journal of Medicine",
      "year": 2012,
      "citationCount": 2000,
      "doi": "10.1056/nejmoa1206797",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1206797",
      "verified": true
    },
    {
      "title": "Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure",
      "journal": "New England Journal of Medicine",
      "year": 2020,
      "citationCount": 1736,
      "doi": "10.1056/nejmoa2030183",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2030183",
      "verified": true
    },
    {
      "title": "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial",
      "journal": "The Lancet",
      "year": 2018,
      "citationCount": 1682,
      "doi": "10.1016/s0140-6736(18)32261-x",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(18)32261-x",
      "verified": true
    },
    {
      "title": "Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol",
      "journal": "New England Journal of Medicine",
      "year": 2020,
      "citationCount": 1440,
      "doi": "10.1056/nejmoa1912387",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1912387",
      "verified": true
    },
    {
      "title": "Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management",
      "journal": "European Heart Journal",
      "year": 2015,
      "citationCount": 1364,
      "doi": "10.1093/eurheartj/ehv043",
      "sourceUrl": "https://doi.org/10.1093/eurheartj/ehv043",
      "verified": true
    },
    {
      "title": "2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult",
      "journal": "Canadian Journal of Cardiology",
      "year": 2016,
      "citationCount": 1167,
      "doi": "10.1016/j.cjca.2016.07.510",
      "sourceUrl": "https://doi.org/10.1016/j.cjca.2016.07.510",
      "verified": true
    },
    {
      "title": "Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease",
      "journal": "New England Journal of Medicine",
      "year": 2020,
      "citationCount": 1116,
      "doi": "10.1056/nejmoa2030186",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2030186",
      "verified": true
    },
    {
      "title": "Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol",
      "journal": "New England Journal of Medicine",
      "year": 2017,
      "citationCount": 950,
      "doi": "10.1056/nejmoa1615758",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1615758",
      "verified": true
    },
    {
      "title": "Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease",
      "journal": "New England Journal of Medicine",
      "year": 2016,
      "citationCount": 827,
      "doi": "10.1056/nejmoa1600176",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1600176",
      "verified": true
    },
    {
      "title": "2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults",
      "journal": "Canadian Journal of Cardiology",
      "year": 2021,
      "citationCount": 797,
      "doi": "10.1016/j.cjca.2021.03.016",
      "sourceUrl": "https://doi.org/10.1016/j.cjca.2021.03.016",
      "verified": true
    },
    {
      "title": "2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult",
      "journal": "Canadian Journal of Cardiology",
      "year": 2013,
      "citationCount": 772,
      "doi": "10.1016/j.cjca.2012.11.032",
      "sourceUrl": "https://doi.org/10.1016/j.cjca.2012.11.032",
      "verified": true
    },
    {
      "title": "2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations",
      "journal": "Canadian Journal of Cardiology",
      "year": 2009,
      "citationCount": 771,
      "doi": "10.1016/s0828-282x(09)70715-9",
      "sourceUrl": "https://doi.org/10.1016/s0828-282x(09)70715-9",
      "verified": true
    },
    {
      "title": "Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus",
      "journal": "Circulation",
      "year": 2019,
      "citationCount": 755,
      "doi": "10.1161/circulationaha.118.038868",
      "sourceUrl": "https://doi.org/10.1161/circulationaha.118.038868",
      "verified": true
    },
    {
      "title": "Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia",
      "journal": "New England Journal of Medicine",
      "year": 2020,
      "citationCount": 752,
      "doi": "10.1056/nejmoa1913805",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1913805",
      "verified": true
    },
    {
      "title": "Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial",
      "journal": "The Lancet",
      "year": 2013,
      "citationCount": 718,
      "doi": "10.1016/s0140-6736(13)60683-2",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(13)60683-2",
      "verified": true
    },
    {
      "title": "Effect of a Low–Glycemic Index or a High–Cereal Fiber Diet on Type 2 Diabetes",
      "journal": "JAMA",
      "year": 2008,
      "citationCount": 714,
      "doi": "10.1001/jama.2008.808",
      "sourceUrl": "https://doi.org/10.1001/jama.2008.808",
      "verified": true
    },
    {
      "title": "The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension",
      "journal": "Canadian Journal of Cardiology",
      "year": 2015,
      "citationCount": 692,
      "doi": "10.1016/j.cjca.2015.02.016",
      "sourceUrl": "https://doi.org/10.1016/j.cjca.2015.02.016",
      "verified": true
    },
    {
      "title": "Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events",
      "journal": "New England Journal of Medicine",
      "year": 2010,
      "citationCount": 664,
      "doi": "10.1056/nejmoa1001121",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1001121",
      "verified": true
    },
    {
      "title": "Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial",
      "journal": "The Lancet Diabetes & Endocrinology",
      "year": 2019,
      "citationCount": 654,
      "doi": "10.1016/s2213-8587(19)30180-9",
      "sourceUrl": "https://doi.org/10.1016/s2213-8587(19)30180-9",
      "verified": true
    },
    {
      "title": "Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk",
      "journal": "New England Journal of Medicine",
      "year": 2022,
      "citationCount": 630,
      "doi": "10.1056/nejmoa2210645",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2210645",
      "verified": true
    },
    {
      "title": "Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease",
      "journal": "New England Journal of Medicine",
      "year": 2016,
      "citationCount": 609,
      "doi": "10.1056/nejmoa1600175",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1600175",
      "verified": true
    },
    {
      "title": "Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial",
      "journal": "The Lancet",
      "year": 2019,
      "citationCount": 599,
      "doi": "10.1016/s0140-6736(19)31150-x",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(19)31150-x",
      "verified": true
    },
    {
      "title": "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial",
      "journal": "The Lancet Diabetes & Endocrinology",
      "year": 2017,
      "citationCount": 578,
      "doi": "10.1016/s2213-8587(17)30313-3",
      "sourceUrl": "https://doi.org/10.1016/s2213-8587(17)30313-3",
      "verified": true
    },
    {
      "title": "Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children",
      "journal": "Canadian Journal of Cardiology",
      "year": 2018,
      "citationCount": 574,
      "doi": "10.1016/j.cjca.2018.02.022",
      "sourceUrl": "https://doi.org/10.1016/j.cjca.2018.02.022",
      "verified": true
    },
    {
      "title": "Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children",
      "journal": "Canadian Journal of Cardiology",
      "year": 2020,
      "citationCount": 572,
      "doi": "10.1016/j.cjca.2020.02.086",
      "sourceUrl": "https://doi.org/10.1016/j.cjca.2020.02.086",
      "verified": true
    },
    {
      "title": "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus",
      "journal": "Circulation",
      "year": 2019,
      "citationCount": 550,
      "doi": "10.1161/circulationaha.119.040130",
      "sourceUrl": "https://doi.org/10.1161/circulationaha.119.040130",
      "verified": true
    },
    {
      "title": "Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease",
      "journal": "Circulation",
      "year": 2019,
      "citationCount": 548,
      "doi": "10.1161/circulationaha.119.042375",
      "sourceUrl": "https://doi.org/10.1161/circulationaha.119.042375",
      "verified": true
    },
    {
      "title": "Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management",
      "journal": "The Lancet Diabetes & Endocrinology",
      "year": 2019,
      "citationCount": 516,
      "doi": "10.1016/s2213-8587(18)30315-2",
      "sourceUrl": "https://doi.org/10.1016/s2213-8587(18)30315-2",
      "verified": true
    },
    {
      "title": "Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension",
      "journal": "Canadian Journal of Cardiology",
      "year": 2016,
      "citationCount": 466,
      "doi": "10.1016/j.cjca.2016.02.066",
      "sourceUrl": "https://doi.org/10.1016/j.cjca.2016.02.066",
      "verified": true
    },
    {
      "title": "Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease",
      "journal": "JAMA",
      "year": 2019,
      "citationCount": 446,
      "doi": "10.1001/jama.2019.16585",
      "sourceUrl": "https://doi.org/10.1001/jama.2019.16585",
      "verified": true
    },
    {
      "title": "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus",
      "journal": "Circulation",
      "year": 2020,
      "citationCount": 427,
      "doi": "10.1161/circulationaha.119.044183",
      "sourceUrl": "https://doi.org/10.1161/circulationaha.119.044183",
      "verified": true
    },
    {
      "title": "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study",
      "journal": "Atherosclerosis",
      "year": 2018,
      "citationCount": 400,
      "doi": "10.1016/j.atherosclerosis.2018.06.002",
      "sourceUrl": "https://doi.org/10.1016/j.atherosclerosis.2018.06.002",
      "verified": true
    },
    {
      "title": "1998 clinical practice guidelines for the management of diabetes in Canada",
      "journal": "Canadian Medical Association Journal",
      "year": 1998,
      "citationCount": 379,
      "doi": null,
      "sourceUrl": "https://openalex.org/W1506652147",
      "verified": true
    },
    {
      "title": "The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy",
      "journal": "Canadian Journal of Cardiology",
      "year": 2010,
      "citationCount": 374,
      "doi": "10.1016/s0828-282x(10)70379-2",
      "sourceUrl": "https://doi.org/10.1016/s0828-282x(10)70379-2",
      "verified": true
    },
    {
      "title": "Effect of Legumes as Part of a Low Glycemic Index Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus",
      "journal": "Archives of Internal Medicine",
      "year": 2012,
      "citationCount": 369,
      "doi": "10.1001/2013.jamainternmed.70",
      "sourceUrl": "https://doi.org/10.1001/2013.jamainternmed.70",
      "verified": true
    },
    {
      "title": "Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease",
      "journal": "New England Journal of Medicine",
      "year": 2016,
      "citationCount": 368,
      "doi": "10.1056/nejmoa1600177",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1600177",
      "verified": true
    },
    {
      "title": "Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract",
      "journal": "European Heart Journal",
      "year": 2018,
      "citationCount": 367,
      "doi": "10.1093/eurheartj/ehy182",
      "sourceUrl": "https://doi.org/10.1093/eurheartj/ehy182",
      "verified": true
    },
    {
      "title": "Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a<i>Diabetes Care</i>Editors’ Expert Forum",
      "journal": "Diabetes Care",
      "year": 2017,
      "citationCount": 363,
      "doi": "10.2337/dci17-0057",
      "sourceUrl": "https://doi.org/10.2337/dci17-0057",
      "verified": true
    },
    {
      "title": "Ticagrelor in Patients with Stable Coronary Disease and Diabetes",
      "journal": "New England Journal of Medicine",
      "year": 2019,
      "citationCount": 344,
      "doi": "10.1056/nejmoa1908077",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1908077",
      "verified": true
    },
    {
      "title": "Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy",
      "journal": "European Journal of Preventive Cardiology",
      "year": 2019,
      "citationCount": 342,
      "doi": "10.1177/2047487319864671",
      "sourceUrl": "https://doi.org/10.1177/2047487319864671",
      "verified": true
    },
    {
      "title": "Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease",
      "journal": "Circulation",
      "year": 2019,
      "citationCount": 340,
      "doi": "10.1161/circulationaha.119.044235",
      "sourceUrl": "https://doi.org/10.1161/circulationaha.119.044235",
      "verified": true
    },
    {
      "title": "The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein",
      "journal": "American Journal of Clinical Nutrition",
      "year": 2008,
      "citationCount": 332,
      "doi": "10.1093/ajcn/87.1.114",
      "sourceUrl": "https://doi.org/10.1093/ajcn/87.1.114",
      "verified": true
    },
    {
      "title": "Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction",
      "journal": "Circulation",
      "year": 2019,
      "citationCount": 326,
      "doi": "10.1161/circulationaha.119.039996",
      "sourceUrl": "https://doi.org/10.1161/circulationaha.119.039996",
      "verified": true
    },
    {
      "title": "Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults",
      "journal": "Canadian Journal of Cardiology",
      "year": 2017,
      "citationCount": 319,
      "doi": "10.1016/j.cjca.2017.03.005",
      "sourceUrl": "https://doi.org/10.1016/j.cjca.2017.03.005",
      "verified": true
    },
    {
      "title": "Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials",
      "journal": "European Journal of Clinical Nutrition",
      "year": 2014,
      "citationCount": 315,
      "doi": "10.1038/ejcn.2014.8",
      "sourceUrl": "https://doi.org/10.1038/ejcn.2014.8",
      "verified": true
    }
  ],
  "awards": [],
  "timeline": [],
  "openalexId": "https://openalex.org/A5080414941",
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/commons/thumb/2/2b/Bajaj_Auto_Ltd_logo.svg/330px-Bajaj_Auto_Ltd_logo.svg.png"
}